2025
Activity-Dependent Effects of ERK1/2 on Hepatic Ischemia-Reperfusion Injury
Kim J, Hong S, Lee A, Kumar S, Suchi M, Park J. Activity-Dependent Effects of ERK1/2 on Hepatic Ischemia-Reperfusion Injury. Transplantation Proceedings 2025 PMID: 40796392, DOI: 10.1016/j.transproceed.2025.07.005.Peer-Reviewed Original ResearchHepatic ischemia-reperfusion injuryIschemia-reperfusion injuryERK1/2 activationLiver injuryActivity-dependent effectsResponse to IRIEnd-stage liver diseaseDose of trametinibAnalysis of cell death pathwaysEffect of ERK1/2Extracellular signal-regulated kinaseExpression of ferroptosis markersSignal-regulated kinaseSerum markersModulation of ERK1/2 activityLiver transplantationMEK1/2 inhibitorReperfusion timeMolecular analysisRat modelIschemia-reperfusionLiver ischemiaCell death pathwaysHistological assessmentLiver diseaseLiver transplant practices in the era of normothermic machine perfusion in the United States
Okumura K, Dhand A, Hasjim B, Misawa R, Sogawa H, Veillette G, Nishida S. Liver transplant practices in the era of normothermic machine perfusion in the United States. World Journal Of Transplantation 2025, 15: 100427. PMID: 40535506, PMCID: PMC11886287, DOI: 10.5500/wjt.v15.i2.100427.Peer-Reviewed Original ResearchLiver transplantationLong preservation timeSurvival outcomesPost-transplant survival outcomesUnited StatesOlder recipient ageTime of surgeryMachine perfusionLiver machine perfusionPost-transplant survivalPreservation timeShort preservation timeUtilization of donorsLT recipientsNormothermic machine perfusionRecipient ageLiver allograftsSubgroup analysisDCD organsTransplant practiceAllograftRecipientsSurvivalReperfusionCirculatory deathClinical and Genetic Profile of Pediatric and Adult Wilson Disease in India
Kulkarni A, Bale G, Vishnubotla R, Rambhatla A, Sharma M, Sabhapandit S, Chintam A, Alla M, Venishetty S, Iyengar S, Komalla R, Ramachandran S, Menon B, Kalapala R, Gupta R, Rao P, Reddy D, Schilsky M, Reddy K. Clinical and Genetic Profile of Pediatric and Adult Wilson Disease in India. Gastro Hep Advances 2025, 100717. DOI: 10.1016/j.gastha.2025.100717.Peer-Reviewed Original ResearchAcute-on-chronic liver failureTransplant-free survivalAcute liver failureLiver failureATP7B mutationsMedian duration of follow-upSingle-center retrospective studyGenetic profile of patientsTransjugular intrahepatic portosystemic shuntDuration of follow-upPathogenic ATP7B variantsLiving donor liver transplantationKaplan Meier analysisIntrahepatic portosystemic shuntDonor liver transplantationGenetic profileProfile of patientsDisorder of copper metabolismMedian durationDecompensated cirrhosisMeier analysisClinical presentationPediatric patientsPediatric groupLiver transplantationRisk Factors in Patients Who Had Prior Renal or Liver Transplant Undergoing Primary Total Hip Arthroplasty
Gill V, Boddu S, Mansour E, Abu Jawdeh B, Khan M, McGary A, Clarke H, Spangehl M, Abdel M, Ledford C, Bingham J. Risk Factors in Patients Who Had Prior Renal or Liver Transplant Undergoing Primary Total Hip Arthroplasty. Journal Of Clinical Medicine 2025, 14: 3486. PMID: 40429481, PMCID: PMC12111864, DOI: 10.3390/jcm14103486.Peer-Reviewed Original ResearchAmerican Society of Anesthesiologists classSolid organ transplantationAmerican Society of Anesthesiologists class 4Associated with high mortalitySurgical complicationsAcute medical complicationsRenal transplantationLiver transplantationMedical complicationsOlder agePeri-operative risk profileOrgan transplantationHistory of solid organ transplantationMedian follow-up periodRisk factorsLikelihood of surgical complicationsTotal hip arthroplastyKaplan-Meier survival analysisRate of reoperationHigher mortalityAssociated with higher riskProportion of patientsFollow-up periodEstimate median survivalLow surgical complicationsFrom embedded interprofessional clinics to expanded alcohol-associated liver disease programs.
Winder G, Arab J, Goswami Banerjee A, Bryce K, Fipps D, Hussain F, Im G, Omary L, Patel A, Patel S, Rubman S, Serper M, Shenoy A, Suzuki J, Zimbrean P, Brown K, Abouljoud M, Mellinger J. From embedded interprofessional clinics to expanded alcohol-associated liver disease programs. Liver Transplantation 2025 PMID: 40359009, DOI: 10.1097/lvt.0000000000000638.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseAUD careLong-term patient relationshipsCare delivery strategiesHazardous alcohol usePatient populationInterprofessional clinicPalliative carePrimary careCare elementsCare frameworkIll patient populationPatient relationshipHealthcare systemLiver transplantationHarm reductionDisease programsCareAlcohol useLiver diseaseEnhanced supportChronic liver diseaseEating disorder treatmentCollaborative modelDisorder treatmentAcute Response of Hepatocyte MRP2 Internalization as an Indicator of Ischemia-reperfusion Injury in Liver Transplantation
Monti C, Hong S, Lee A, Hong J, Eriksen C, Joshi A, Dash R, Audi S, Lee W, Kumar S, Kim J. Acute Response of Hepatocyte MRP2 Internalization as an Indicator of Ischemia-reperfusion Injury in Liver Transplantation. Transplantation 2025, 109: 1495-1505. PMID: 40320583, DOI: 10.1097/tp.0000000000005418.Peer-Reviewed Original ResearchConceptsMultidrug resistance-associated protein 2Ischemia-reperfusion injuryNormothermic machine perfusionLiver transplantationIschemia timeGraft viabilityPerfusion levelsHepatic ischemia-reperfusion injurySerum aminotransferase levelsInverse correlationAcute responseLevels of liver injury markersLiver injury markersLiver graft viabilityImmunofluorescence colocalization analysisMrp2 internalizationAminotransferase levelsMRP2-mediated transport activityInjury markersRat modelHuman LTArginase 1Loss of functionBiliary excretionSodium fluoresceinLiver Transplant Provider Perspectives on Posttransplant Management of Alcohol Use Disorder
Cote M, Cloonan D, Li S, Razak S, Singh R, Coe T, Zimbrean P, Andrews S, Ivkovic A, Bartels S, Chadha R, Bethea E, Yeh H, Lim N, Dageforde L. Liver Transplant Provider Perspectives on Posttransplant Management of Alcohol Use Disorder. Transplantation Direct 2025, 11: e1766. PMID: 40078821, PMCID: PMC11896101, DOI: 10.1097/txd.0000000000001766.Peer-Reviewed Original ResearchAUD careAlcohol use disorderAlcohol-associated liver diseasePost-LTLiver transplantationManagement of alcohol use disorderLiver diseaseTreatment of alcohol use disordersTreat alcohol use disorderUse disorderPost-LT treatmentPost-LT patientsMental health professionalsMedication-Assisted TherapyAnalysis of categorical variablesAmerican SocietyNurse coordinatorPerceived BarriersHealth professionalsProvider perspectiveChi-square testPosttransplant managementUnivariate analysis of categorical variablesVolume tertilesAlcohol abstinenceDevelopment of the natural history component of an early economic model for primary sclerosing cholangitis
Bowlus C, Levy C, Kowdley K, Kachru N, Jeyakumar S, Rodriguez-Guadarrama Y, Smith N, Briggs A, Sculpher M, Ollendorf D. Development of the natural history component of an early economic model for primary sclerosing cholangitis. Orphanet Journal Of Rare Diseases 2025, 20: 133. PMID: 40102907, PMCID: PMC11921552, DOI: 10.1186/s13023-025-03658-8.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsTransplant-free survivalProportion of patientsRecurrent PSCLiver transplantationDisease progressionOverall survivalSclerosing cholangitisSecondary cancersCumulative incidenceCumulative incidence of secondary cancersIncidence of secondary cancersChronic cholestatic diseasePrimary sclerosing cholangitisProgression to cirrhosisLifetime quality-adjusted life yearsBackgroundPrimary sclerosing cholangitisMarkov cohort modelInflammatory bowel diseaseEconomic modelGallbladder cancerEstimates of disease progressionCholestatic diseasesFibrosis stageLiver failureWorse clinical outcomes of TACE when liver function is decompensated in a cohort of patients with cirrhosis and HCC waiting for liver transplantation
Makarova E, Fan X, Farooqi I, Bakhl K, Murphy T, Stonesifer E, Faust A. Worse clinical outcomes of TACE when liver function is decompensated in a cohort of patients with cirrhosis and HCC waiting for liver transplantation. Journal Of Liver Transplantation 2025, 17: 100257. DOI: 10.1016/j.liver.2024.100257.Peer-Reviewed Original ResearchTrans arterial chemoembolizationDecompensated liver functionHepatocellular carcinomaLiver functionLiver transplantationClinical outcomesRetrospective cohort study of patientsClinical outcomes of patientsWorsening of liver functionCohort study of patientsCompensated liver functionOutcomes of patientsCohort of patientsRetrospective cohort studyStudy of patientsStatistically significant differenceLocoregional therapyArterial chemoembolizationDecompensated cirrhosisPoor outcomePrimary statistical analysisPatientsCirrhosisTransplantationSignificant differenceRecent advances in the management of pediatric cholestatic liver diseases
Mysore K, Cheng K, Suri L, Fawaz R, Mavis A, Kogan‐Liberman D, Mohammad S, Taylor S. Recent advances in the management of pediatric cholestatic liver diseases. Journal Of Pediatric Gastroenterology And Nutrition 2025, 80: 549-558. PMID: 39840645, PMCID: PMC11961318, DOI: 10.1002/jpn3.12462.Peer-Reviewed Original ResearchPediatric cholestatic liver diseasesCholestatic liver diseaseIleal bile acid transporterAlagille syndromeSlow disease progressionLiver diseaseBile acid transporterMedical therapyIleal bile acid transporter inhibitorClinical trialsDisease progressionProgressive familial intrahepatic cholestasisFamilial intrahepatic cholestasisPediatric liver transplantationBile acid toxicityCurative medical therapyAcid transportImprove patient qualityIntrahepatic cholestasisBiliary atresiaSurgical managementRare conditionLiver transplantationNutritional supportUnderlying etiologyChapter 30 Wilson disease⊛
To U, Schilsky M. Chapter 30 Wilson disease⊛. 2025, 841-859. DOI: 10.1016/b978-0-443-26711-6.00030-5.Peer-Reviewed Original ResearchWilson's diseaseAutosomal recessive disorderATP7B proteinNegative copper balanceDiverse phenotypesATP7B geneUnexplained liver diseaseLong-term survivalCopper transportBiochemical testsGenetic testingRecessive disorderMetabolic correctionLiver transplantationMedical historyHepatic symptomsLiver diseaseATP7BCopper excretionNeurological assessmentDietary restrictionIncreased excretionCopper balancePsychiatric symptomsExcretionCirrhosis and Truly Elective Major Surgery
Jakab S, Oprea A. Cirrhosis and Truly Elective Major Surgery. 2025, 249-258. DOI: 10.1093/med/9780190902001.003.0021.Peer-Reviewed Original ResearchPrevalence of chronic liver diseasePerioperative management of patientsPreoperative risk evaluationPresence of cirrhosisType of surgeryComplications of cirrhosisManagement of patientsEfficacy of therapyChronic liver diseaseLiver synthetic dysfunctionSynthetic dysfunctionOverall prognosisPostoperative complicationsDiagnosing cirrhosisPortal hypertensionLiver transplantationPerioperative managementPatient comorbiditiesSurgical proceduresCirrhosisLiver diseasePatientsSurgical teamScoring systemSurgery
2024
Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease
Jaoudeh R, Hartmann P, Olson O, Gupta O, Kumar S, Ibrahim S, Fawaz R, Aqul A, Hassan S. Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease. Journal Of Pediatric Gastroenterology And Nutrition 2024, 80: 14-24. PMID: 39526564, DOI: 10.1002/jpn3.12402.Peer-Reviewed Original ResearchGLP-1RABody mass indexLiver diseasePediatric patientsPediatric obesityEfficacy of GLP-1RADisease progressionGlucagon-like peptide-1 receptor agonistsSteatotic liver diseaseManagement of pediatric patientsPeptide-1 receptor agonistsClinical management of pediatric patientsAdverse liver outcomesInduce weight lossLong-term efficacyHepatic manifestation of obesityLiver enzyme levelsAlternative therapeutic strategiesHalting disease progressionManifestation of obesityNonalcoholic fatty liver diseaseChildhood obesity ratesFatty liver diseaseReceptor agonistsLiver transplantationLong-term Outcomes Following Colectomy and Liver Transplantation for Inflammatory Bowel Disease with Primary Sclerosing Cholangitis.
Matar A, Falconer E, LaBella M, Kapadia M, Justiniano C, Olortegui K, Steinhagen R, Schultz K, Pratap A, Leeds I, Weaver L, Gaertner W, Finger E, Thompson M, Fair L, Fichera A, Lovasik B, Chapman W, McGeoch C, Camacho M, Kazimi M, Kim S, Shaffer V, Srinivasan J. Long-term Outcomes Following Colectomy and Liver Transplantation for Inflammatory Bowel Disease with Primary Sclerosing Cholangitis. Annals Of Surgery 2024 PMID: 39258375, PMCID: PMC12184207, DOI: 10.1097/sla.0000000000006533.Peer-Reviewed Original ResearchTotal abdominal colectomyLong-term outcomesIleal pouch anal anastomosisMedically refractory diseaseLiver transplantationPSC-IBDRecurrent PSCRefractory diseaseBiliary complicationsMedian timeLong-term outcomes of patientsBowel diseasePost-LT survivalOutcomes of patientsPrimary sclerosing cholangitisFraction of patientsPSC-IBD patientsLong-term survivalInflammatory bowel diseasePost-LTSclerosing cholangitisPediatric patientsAbdominal colectomyEnd ileostomyLT survivalThe Italian experience on liver transplantation for unresectable peri-hilar cholangiocarcinoma: a national survey and future perspectives
Gringeri E, Furlanetto A, Billato I, Cescon M, De Carlis L, Mazzaferro V, Romagnoli R, De Simone P, Vivarelli M, Di Benedetto F, Ravaioli M, Lauterio A, Sposito C, Patrono D, Ghinolfi D, Moccheggiani F, Di Sandro S, D’Amico F, Lanari J, Gambato M, Trapani S, Bergamo F, Cardillo M, Burra P, Cillo U. The Italian experience on liver transplantation for unresectable peri-hilar cholangiocarcinoma: a national survey and future perspectives. Updates In Surgery 2024, 76: 2505-2513. PMID: 39210194, DOI: 10.1007/s13304-024-01889-1.Peer-Reviewed Original ResearchNeoadjuvant radio-chemotherapyPerihilar cholangiocarcinomaLiver transplantationGroup 1Radio-chemotherapyGroup 2Standard of care chemotherapyRisk of cancer-related deathInclusion criteriaPeri-hilar cholangiocarcinomaRecurrence-free survivalResults of LTRisk regression analysisCancer-related deathsLiver transplant centersMayo protocolNeoadjuvant regimenNeoadjuvant treatmentCare chemotherapyOverall survivalProspective studyMayo ClinicHazard ratioTransplant centersIneffective treatmentCOBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls
Kowdley K, Hirschfield G, Coombs C, Malecha E, Bessonova L, Li J, Rathnayaka N, Mells G, Jones D, Trivedi P, Hansen B, Smith R, Wason J, Hiu S, Kareithi D, Mason A, Bowlus C, Muller K, Carbone M, Berenguer M, Milkiewicz P, Adekunle F, Villamil A. COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls. The American Journal Of Gastroenterology 2024, 120: 390-400. PMID: 39140490, PMCID: PMC11774195, DOI: 10.14309/ajg.0000000000003029.Peer-Reviewed Original ResearchPrimary biliary cholangitisObeticholic acidClinical outcomesFunctional unblindingPlacebo armBiliary cholangitisConfirmatory trialsUS healthcare claims databasePrimary biliary cholangitis patientsOCA therapyObeticholic acid treatmentPrimary composite endpointAs-treated analysisHealthcare claims databaseNegative clinical outcomesUncontrolled ascitesPlacebo patientsHepatic decompensationPrimary endpointLiver transplantationComposite endpointCommercial therapySafety signalsPlaceboTreatment crossoverAdvocating for a “shift-to-left” in transplant oncology: left grafts, RAPID and dual graft
Cillo U, Furlanetto A, Gringeri E, Bertacco A, Marchini A, Rosso E, Bassi D, D’Amico F, Line P. Advocating for a “shift-to-left” in transplant oncology: left grafts, RAPID and dual graft. Updates In Surgery 2024, 1-14. PMID: 39120859, DOI: 10.1007/s13304-024-01919-y.Peer-Reviewed Original ResearchLiving donor liver transplantationRisk of small-for-size syndromeSmall-for-size syndromeDual-graft living donor liver transplantationHigh-volume transplant centerDonor liver transplantationDonor-recipient matchingShortage of graftsLeft-lobeLiver transplantationRight-lobeOncological indicationsTransplant oncologyDonor hepatectomyDual graftsTransplant centersHigh riskLeft graftGraftHighlights of Enhanced Recovery After Surgery (ERAS) Programs for Liver Transplantation
Guzzi J, Strand E, Hussain N, Batra R, Deshpande R. Highlights of Enhanced Recovery After Surgery (ERAS) Programs for Liver Transplantation. Current Transplantation Reports 2024, 11: 125-130. DOI: 10.1007/s40472-024-00442-8.Peer-Reviewed Original ResearchAttachment Styles and Quality of Life among Liver Transplant Recipients
Coskun A, Tosun S, Luo J, Zhang Y, Emre S, Zimbrean P. Attachment Styles and Quality of Life among Liver Transplant Recipients. Health Behavior And Policy Review 2024, 11: 1672-1686. DOI: 10.14485/hbpr.11.4.4.Peer-Reviewed Original ResearchQuality of lifeAttachment styleLiver transplant recipientsTransplant recipientsPatient-physician relationshipPresence of depressionCross-sectional studyPatients' attachment styleAssessed attachment styleChronic illnessQOL scoresQoLChronic painPsychological factorsRelationship styleAnxietyDepressionPost-transplantationLiver transplantationTransplant candidatesTransplantationAssociationRecipientsLiverStyleNormothermic Machine Perfusion Is Associated With Improvement in Mortality and Graft Failure in Donation After Cardiac Death Liver Transplant Recipients in the United States
Okumura K, Dhand A, Misawa R, Sogawa H, Veillette G, Nishida S. Normothermic Machine Perfusion Is Associated With Improvement in Mortality and Graft Failure in Donation After Cardiac Death Liver Transplant Recipients in the United States. Transplantation Direct 2024, 10: e1679. PMID: 38988687, PMCID: PMC11230788, DOI: 10.1097/txd.0000000000001679.Peer-Reviewed Original ResearchNormothermic machine perfusion groupNormothermic machine perfusionLiver transplantationLT recipientsGraft survivalPropensity score matchingOverall survivalGraft failureDCD LT recipientsTwo-year overall survivalEnd-stage liver disease scoreMultivariate Cox regression analysisAdult LT recipientsScore matchingLiver transplant recipientsLiver Disease scoreCox regression analysisMachine perfusionUnited Network for Organ SharingUtilization of donationPosttransplant patientsTransplant recipientsAssociated with improvementsNon-MPSOlder donors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply